|Follow up complete
|Study Start Date:
|Study Made Public:
A Phase 1/2a clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and of MF59- or AS01B-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants
HVTN 120 is a Phase I/IIa clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and bivalent subtype C gp120 (with MF59 or AS01B).
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.